Published in Tidsskr Nor Laegeforen on May 10, 1996
[Growth factors and cytokines in hematologic diseases. Use in aplastic anemia]. Tidsskr Nor Laegeforen (1996) 0.75
[Treatment with growth factors and cytokines in hematological diseases]. Tidsskr Nor Laegeforen (1996) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet (1992) 2.22
Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis (1985) 2.14
Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol (1983) 2.05
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54
The human mixed lymphocyte-endothelium culture interaction. Transplantation (1975) 1.50
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) Br J Haematol (1991) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients. J Intern Med (1994) 1.40
[Prioritizing in hospital departments]. Tidsskr Nor Laegeforen (1993) 1.39
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Injury to human endothelial cells in culture induced by low density lipoproteins. Scand J Clin Lab Invest (1979) 1.38
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer (2007) 1.33
LDL-induced cytotoxicity and its inhibition by anti-oxidant treatment in cultured human endothelial cells and fibroblasts. Atherosclerosis (1983) 1.32
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr Scand (1970) 1.29
Effects of divalent cations and various vasoactive and haemostatically active agents on the integrity of monolayers of cultured human endothelial cells. Thromb Res (1981) 1.21
Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Qual Life Res (1999) 1.20
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
Intestinal telangiectasis in Turner's syndrome. Endoscopy (1981) 1.11
Deficient lymphoid cell-mediated, PHA-induced cytotoxicity in rheumatoid arthritis patients. Scand J Immunol (1975) 1.10
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Evidence that tumour necrosis factor (TNF) is not constitutively present in vivo. The association of TNF with freshly isolated monocytes reflects a rapid in vitro production. Scand J Immunol (1988) 1.06
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer (2004) 1.05
A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant (2000) 1.03
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol (2001) 1.01
A 69-year-old man with chronic obstructive pulmonary disease, pancreatic insufficiency and elevated sweat electrolytes. Acta Med Scand (1981) 1.00
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol (1999) 0.96
The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation. Bone Marrow Transplant (1999) 0.96
Endothelial injury induced by bacterial endotoxin: effect of complement depletion. Eur J Clin Invest (1975) 0.95
Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma. Cancer (1987) 0.95
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant (2002) 0.94
Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints. Ann Rheum Dis (1985) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
Activation of human monocytes by mediators from lymphocytes stimulated with Corynebacterium parvum. Acta Pathol Microbiol Scand C (1979) 0.93
Thrombin-induced shape changes of cultured endothelial cells: metabolic and functional observations. Thromb Res (1983) 0.92
Haemostatic studies in osteogenesis imperfecta. Scand J Haematol (1984) 0.92
The catabolic fate of hyaluronic acid. Connect Tissue Res (1986) 0.91
Thrombin induces thromboplastin synthesis in cultured vascular endothelial cells. Thromb Haemost (1985) 0.91
Structural and functional properties of blood monocytes cultured in vitro. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 0.91
Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study. J Clin Oncol (1999) 0.91
Stimulation of human lymphocytes by allogeneic endothelial cells in vitro. Tissue Antigens (1974) 0.90
Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1994) 0.90
DNA synthesis in rat aortic endothelium; effect of bacterial endotoxin and trauma. Microvasc Res (1974) 0.90
Cytokine-associated tissue injury and lethality in mice: a comparative study. Clin Immunol Immunopathol (1991) 0.90
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Antiphospholipid antibodies in pre-eclamptic women: relation to growth retardation and neonatal outcome. Acta Obstet Gynecol Scand (1992) 0.88
Biosynthesis of proteoglycans and hyaluronate in rabbit corneal fibroblast cultures. Variation with age of the cell line and effect of foetal calf serum. Exp Eye Res (1981) 0.88
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Pathogenesis of disseminated intravascular coagulation. Hamatol Bluttransfus (1970) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Injury to cultured endothelial cells induced by low density lipoproteins: protection by high density lipoproteins. Scand J Clin Lab Invest (1979) 0.87
Induction of disseminated intravascular coagulation in the factor XII-deficient fowl. Morphological effects of liquoid, bacterial endotoxin and tissue thromboplastin in the normal and anticoagulated fowl. Thromb Diath Haemorrh (1973) 0.87
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87
Stimulation of human lymphocytes by cultured allogeneic skin and endothelial cells in vitro. Transplantation (1975) 0.87
The effect of serum lipoproteins on cholesterol content and sterol exchange in cultured human endothelial cells. Biochim Biophys Acta (1979) 0.87
Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol (1995) 0.86
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Inhibitory effect of human mononuclear phagocytes on DNA synthesis in stimulated lymphocytes. Acta Pathol Microbiol Scand C (1977) 0.86
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer (2004) 0.86
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis (1991) 0.86
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol (1999) 0.86
Platelets and the triggering mechanism of intravascular coagulation. Br J Haematol (1970) 0.86
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol (2001) 0.86
The effect of thrombin on fibronectin in cultured human endothelial cells. Thromb Res (1985) 0.86
The synthesis of glycosaminoglycans by corneal stroma cells in culture. Exp Cell Res (1974) 0.86
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
The effect of phenylbutazone and chloramphenicol on phagocytosis of radiolabelled Candida albicans by human monocytes cultured in vitro. Acta Pathol Microbiol Scand C (1976) 0.85
Experimental thrombocytopenia induced by Busulphan (Myleran) in rabbits: extremely low platelet levels and intact plasma clotting system. Thromb Diath Haemorrh (1968) 0.85
Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. Clin Genet (1997) 0.85
Proteoglycan biosynthesis in cultures of corneas and corneal stroma cells from adult rabbits. Exp Eye Res (1978) 0.85
Self-therapy for haemophilia in Norway. Effect on transfusion frequency and days lost from work. Acta Med Scand (1979) 0.84
Endotoxin-induced intravascular coagulation and shock in dogs: the role of factor VII. Br J Haematol (1974) 0.84
Ultrastructural identification of umbilical cord vein endothelium in situ and in culture. Cell Tissue Res (1975) 0.84
Leukemia in the central nervous system. Acta Med Scand (1988) 0.84
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45). Scand J Immunol (1990) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood (1992) 0.83
Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand (1999) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Interleukin 8 in serum in granulocytopenic patients with infections. Br J Haematol (1994) 0.83
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. J Immunol (1987) 0.83
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia (2006) 0.83